SynthesisMedicine2019
Therapeutic role of melatonin in migraine prophylaxis: A systematic review.
Synthesis in Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 4 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Efficacy and Safety of Melatonin in Migraine Prophylaxis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Current pain and headache reports · 2026Pooled it
- Circadian Features of Cluster Headache and Migraine: A Systematic Review, Meta-analysis, and Genetic Analysis.Neurology · 2023Pooled it
- Pediatric hypnic headache: a systematic review.Frontiers in neurology · 2023Pooled it
- Efficacy and Safety of Melatonin as Prophylaxis for Migraine in Adults: A Meta-analysis.Journal of oral & facial pain and headache · 2022Pooled it
- The Effect of Melatonin on Reducing the Frequency and Severity of Migraine Attacks: A Double-Blind, Randomized Clinical Trial.Iranian journal of medical sciences · 2024Trial
- The effectiveness of agomelatine on headache severity and frequency in episodic migraine without aura; a parallel randomized controlled trial study.BMC neurology · 2024Trial
- Framework for headache management in pediatric patients with stroke and cerebrovascular lesions: A narrative review.Headache · 2026Review
- Migraine and menopause as converging factors in brain vulnerability: a hypothesis-driven perspective.The journal of headache and pain · 2026Review
- Migraine Management in Japan: Current Approaches and Science Narrative Including an Evidence-based Review.Internal medicine (Tokyo, Japan) · 2026Review
- Expression of melatonin receptors in trigeminal and sphenopalatine ganglia: potential targets for primary headache disorders.The journal of headache and pain · 2025Article
- Chronobiology in Paediatric Neurological and Neuropsychiatric Disorders: Harmonizing Care with Biological Clocks.Journal of clinical medicine · 2024Review
- The Effect of Melatonin on Sleep Disorders in Children with Cerebral Palsy A Randomized Clinical Trial.Iranian journal of child neurology · 2024Article
- Comprehensive list of preventative migraine headache medications without significant drug-drug interactions.Frontiers in neurology · 2024Article
- Efficacy of Melatonin Administration in Reducing Headaches in Children with Migraines without Sleep Disorders.Iranian journal of child neurology · 2024Article
- Tryptophan Metabolism in Central Nervous System Diseases: Pathophysiology and Potential Therapeutic Strategies.Aging and disease · 2023Review
- Migraine signaling pathways: amino acid metabolites that regulate migraine and predispose migraineurs to headache.Molecular and cellular biochemistry · 2022Review
- The Pathogenetic Role of Melatonin in Migraine and Its Theoretic Implications for Pharmacotherapy: A Brief Overview of the Research.Nutrients · 2022Review
- Real-time ultrasound-guided stellate ganglion block for migraine: an observational study.BMC anesthesiology · 2022Observational
- A novel technique of botulinum toxin injection around skull sutures for chronic migraine: A randomized controlled clinical trial.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2022Article
- Administration in Efficacy of Melatonin Reducing Headaches in Children With Migraines and Sleep Disorders: A Randomized Clinical Trial Study.Iranian journal of child neurology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMelatonin is the "clock factor" generated from pineal gland dominating regular circadian rhythm in humans. Migraine is one of the most severe and debilitating primary headache disorders. Thus far, many diseases have been found to associate with melatonin, including the migraine. Therefore, melatonin's therapeutic potential for migraine is drawing attention.
objectivesThe aim of this study is to offer a systematic review of extant data of melatonin in migraine prophylaxis and to provide clinical implications and specific recommendations for future studies. DATA SOURCES AND STUDY
methodsA systematic research was conducted in September 2018 by using PubMed and Google Scholar databases to search for science literature published after 1988.
resultsIn all, 7 eligible articles were identified, including 4 randomized controlled studies and 3 observational studies. Due to high heterogeneities and limited number of studies, meta-analysis was not feasible, and only systematic review was performed. The results show that present evidence cannot claim melatonin's effectiveness according to the conflicting outcomes; however, the two negative outcomes of melatonin not different from placebo and melatonin inferior to amitriptyline are possible under-powering because of methodological, pharmacological, and therapeutic shortcomings. Observational studies also support melatonin's efficacy in migraine. As a result, melatonin is very likely to benefit migraine in prophylaxis and may have a similar effectiveness to other main preventive medications. Immediate-release melatonin 3 mg was established as effective, melatonin receptor agonist (Agomelatine) 25 mg and prolonged-release melatonin 4 mg were observed efficacious in observational studies. Melatonin displayed ineffective in the 2-month trial; thus, 3 months or more may be an enough duration for migraine therapy. Despite melatonin being generally safe, emerging literature is illustrating that a few severe adverse effects can be caused by melatonin, for example, liver injuries, reproductive system dysfunctions, and detrimental immunostimulation.
conclusionsMelatonin is very likely to be a promising alternative for migraine prophylaxis. Current literature examining melatonin's efficacy in migraine prevention is growing, but still limited. Future studies of perfect design in methodology, pharmacology, and therapeutics are needed to achieve a deeper awareness of melatonin's role in migraine as well as more studies to explore the safety issues of melatonin medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.